Irving, United States
Caris Life Sciences, established in 1996, stands at the forefront of TechBio innovations, leading the charge in precision medicine. The company’s commitment to harnessing quality and innovation is evident through their proprietary molecular profiling techniques, notably Whole Exome and Whole Transcriptome Sequencing. By integrating advanced AI and machine learning algorithms, Caris has constructed an extensive clinico-genomic database essential for dissecting the intricacies of diseases.
Headquartered in the United States, with strategic offices in Phoenix, New York, Tokyo, and Basel, Caris delivers services across U.S., Europe, Asia, and beyond. The recent $494.12M Late VC investment, finalized on 01 June 2025, underscores robust investor confidence in Caris's mission to transform healthcare, emphasizing early detection and innovative therapeutic approaches.
